Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AstraZeneca Shuts Bangalore R&D …
by Lisa M. Jarvis
February 3, 2014
| A version of this story appeared in
Volume 92, Issue 5
As part of a plan to focus its research activities on fewer therapeutic areas, AstraZeneca is shutting down its Avishkar R&D site in Bangalore, India. The closure will cost 168 jobs in pharmaceutical development and drug discovery for neglected tropical diseases, tuberculosis, and malaria, all areas AstraZeneca will not pursue further. Work will continue on AZD5847, in Phase II studies for tuberculosis, and AstraZeneca will still make available its compound library to open-innovation partners.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X